SCHEMBL5542550

SCHEMBL5542550

CNCCN(C)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 2/20 0.48
NOS1 P29475 1/20 0.43
NOS2 P35228 1/20 0.43
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
LMNA P02545 4/20 0.39
SLC6A4 P31645 3/20 0.39
SLC6A3 Q01959 3/20 0.39
NPC1 O15118 2/20 0.39
CYP2D6 P10635 2/20 0.39
CYP2C19 P33261 2/20 0.39
MTOR P42345 2/20 0.39
RAB9A P51151 2/20 0.39
CYP3A4 P08684 2/20 0.39
SLC6A2 P23975 2/20 0.39
HTR2C P28335 2/20 0.39
KDM4E B2RXH2 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20284303 0.79 KIF11 (0.42) MEN1KMT2ASLC6A4SLC6A3CYP3A4
Hydrochloric Acid SCHEMBL5539366 0.79 CYP2C9 (0.42) PRMT1NOS1NOS2LMNACYP2C19
SCHEMBL5539145 0.78 KIF11 (0.41) SLC6A4SLC6A3SLC6A2TSHROPRM1
SCHEMBL15362902 0.76 MAPT (0.51) MEN1KMT2ALMNAHTTKIF11
SCHEMBL22542431 0.76 TMEM97 (0.48) PRMT1NOS1NOS2KDM4ECYP2C9
SCHEMBL6241015 0.76 ALDH1A1 (0.46) PRMT1NOS1NOS2LMNACYP2D6
SCHEMBL9760728 0.76 CHRM5 (0.46) PRMT1NOS1NOS2SLC6A2CHRM5
SCHEMBL13261444 0.75 MAPT (0.46) MEN1KMT2ALMNASLC6A4SLC6A3
SCHEMBL5539693 0.75 KIF11 (0.39) MEN1KMT2ALMNASLC6A4SLC6A3
SCHEMBL4616383 0.75 KIF11 (0.44) LMNASLC6A4SLC6A3SLC6A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PRMT1 645/4885NOS1 553/4885NOS2 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.